Last reviewed · How we verify
LY-3185643
At a glance
| Generic name | LY-3185643 |
|---|---|
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Upper respiratory tract infection
- Back pain
- Dyspepsia
- Vomiting
- Administration site bruise
- Asthenia
- Injection site pain
- Injection site rash
- Injection site reaction
- Pyrexia
- Thirst
Key clinical trials
- A Study of LY3185643 and rGlucagon in Healthy Participants (PHASE1)
- A Study of LY3143753 and LY3185643 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |